Preimplantation Genetic Diagnosis in Assisted Reproduction

Size: px
Start display at page:

Download "Preimplantation Genetic Diagnosis in Assisted Reproduction"

Transcription

1 I National Medical Policy Subject: Policy Number: Preimplantation Genetic Diagnosis in Assisted Reproduction NMP245 Effective Date*: October 2005 Updated: September 2017 This National Medical Policy is subject to the terms in the IMPORTANT NOTICE at the end of this document For Medicaid Plans: Please refer to the appropriate State's Medicaid manual(s), publication(s), citations(s) and documented guidance for coverage criteria and benefit guidelines prior to applying Health Net Medical Policies The Centers for Medicare & Medicaid Services (CMS) For Medicare Advantage members please refer to the following for coverage guidelines first: Use Source Reference/Website Link National Coverage Determination (NCD) National Coverage Manual Citation Local Coverage Determination (LCD)* Article (Local)* Other X None Use Health Net Policy Instructions Medicare NCDs and National Coverage Manuals apply to ALL Medicare members in ALL regions. Medicare LCDs and Articles apply to members in specific regions. To access your specific region, select the link provided under Reference/Website and follow the search instructions. Enter the topic and your specific state to find the coverage determinations for your region. *Note: Health Net must follow local coverage determinations (LCDs) of Medicare Administration Contractors (MACs) located outside their service area when those MACs have exclusive coverage of an item or service. (CMS Manual Chapter 4 Section 90.2) Preimplantation Genetic Diagnosis Sep 17 1

2 If more than one source is checked, you need to access all sources as, on occasion, an LCD or article contains additional coverage information than contained in the NCD or National Coverage Manual. If there is no NCD, National Coverage Manual or region specific LCD/Article, follow the Health Net Hierarchy of Medical Resources for guidance. Current Policy Statement Many benefit plans specifically exclude in vitro fertilization (IVF) and related procedures. Health Net does not cover IVF services associated with preimplantation genetic diagnosis (PGD) unless the plan specifically covers IVF. Health Net, Inc. considers preimplantation genetic diagnosis (PGD) as an adjunct to in vitro fertilization (IVF) medically necessary to deselect embryos affected by flawed genetic make-up, when the results of the genetic test will impact clinical decision making and/or clinical outcome, and any of the following are met: 1. Women > 35 years of age to test for suspected aneuploidy - one or a few chromosomes above or below the normal chromosome number, e.g., three number 21 chromosomes or trisomy 21 (characteristic of Down syndrome) is a form of aneuploidy. 2. Couples at high risk for aneuploid pregnancy (e.g., prior aneuploid pregnancy) 3. Couples at high risk for single gene disorders* who meet any of the following: One partner has the diagnosis, is a known carrier or has a family history of a single gene, autosomal dominant chromosomal disorder Both partners are known carriers of a single gene autosomal recessive chromosomal disorder One partner is a known carrier of a single X-linked disorder 4. Couples who already have one child with a genetic problem and are at high risk of having another 5. There have been three or more prior failed attempts at IVF 6. Women with > 2 miscarriages (recurrent pregnancy losses) related to parental structural chromosome abnormality 7. Repeated implantation failure defined as the absence of a gestational sac on ultrasound at 5 weeks post-embryo transfer (e.g., > 3 embryo transfers with high quality embryos or the transfer of 10 embryos in multiple transfers) 8. To determine the sex of an embryo only when there is a documented history of an X-linked disorder, such that deselection of an affected embryo can be made on the basis of sex alone. 9. To evaluate human leukocyte antigen (HLA) status in families with a child with a malignant cancer or genetic disorder who is likely to be cured or whose life expectancy is expected to be substantially prolonged by a cord blood stem cell transplant after all other clinical options have been exhausted, and in whom Preimplantation Genetic Diagnosis Sep 17 2

3 there is no other source of a compatible bone marrow donor other than an HLA matched sibling. *Note: Single gene disorders include autosomal recessive diseases (e.g., cystic fibrosis, beta-thalassemia, Tay-Sachs), autosomal dominant diseases (e.g., Marfan's syndrome, myotonic dystrophy) and X-linked diseases (e.g., Duchenne and Becker's muscular dystrophy, hemophilia, fragile-x syndrome). Note: When the specific criteria noted above are met, we consider the polar body biopsy / cleavage stage embryo biopsy procedure to obtain the cell and the genetic test associated with PGD medically necessary. List of Genetically Determined Disorders Achondroplasia Alpha-1-antitrypsin deficiency Cystic fibrosis Fanconi anemia Hemophilia A and B Muscular dystrophy (Duchenne and Becker) osis type I Phenylketonuria Retinitis pigmentosa Spinal muscular atrophy Fragile X syndrome Rett syndrome Barth's syndrome Down's syndrome Adenosine deaminase deficiency Beta thalassemia Epidermolysis bullosa Gaucher disease Huntington disease Ornithine transcarbamylase (OTC) deficiency Myotonic dystrophy Retinoblastoma Sickle cell disease Tay Sachs disease Lesch-Nyhan syndrome Charcot-Marie-Tooth disease Turner syndrome Health Net, Inc. considers PGD not medically necessary for any of the following because there is a paucity of peer-reviewed studies: 1. The genetic code associated with the condition is not known to allow diagnosis with current genetic testing techniques 2. Genetic diagnosis is uncertain, e.g., due to genetic/molecular heterogeneity or uncertain mode of inheritance 3. PGD for the purposes of carrier testing to determine carrier status of the embryo (determination of carrier status is performed on individuals contemplating reproduction) 4. PGD for adult-onset/late-onset disorders (e.g., Alzheimer's disease; cancer predisposition) Health Net, Inc. considers PGD investigational for any of the following because although studies continue to be done, additional peer-reviewed studies are Preimplantation Genetic Diagnosis Sep 17 3

4 necessary to determine the safety, efficacy and long-term outcomes for these scenarios: 1. PGD for the purpose of HLA typing of an embryo to identify a future suitable stem cell, tissue or organ transplantation donor; PGD has not been established as the standard of care for assessing the suitability of embryos for stem cell transplantation. 2. Testing of embryos for non-medical gender selection or non-medical traits. 3. The affected or sick child has an acute medical condition prohibiting safe stem cell transplantation or has extremely low life expectancy, such that there isn t enough time for the PGD test to be developed, applied and the birth of the HLAmatched sibling. Codes Related To This Policy NOTE: The codes listed in this policy are for reference purposes only. Listing of a code in this policy does not imply that the service described by this code is a covered or noncovered health service. Coverage is determined by the benefit documents and medical necessity criteria. This list of codes may not be all inclusive. On October 1, 2015, the ICD-9 code sets used to report medical diagnoses and inpatient procedures have been replaced by ICD-10 code sets. ICD-10 Codes D56.0- D56.9 Thalassemia D57.0- D Sickle-cell disorders D D61.09 Constitutional aplastic anemia E75.02 Tay-Sachs disease E75.19 Other gangliosidosis E75.4 Neuronal ceroid lipofuscinosis E75.02 Tay-Sachs disease E75.19 Other gangliosidosis E75.4 Neuronal ceroid lipofuscinosis E E72.9 Other disorders of amino-acid metabolism E84.0- E84.9 Cystic Fibrosis G71.0 Muscular dystrophy G71.2 Congenital myopathies O O Supervision of elderly primigravida and multigravida O O Supervision of other high risk pregnancies O33.7 Maternal care for disproportion due to other fetal deformities O35.0XX0- O35.0XX9 Q05.0- Maternal care for known or suspected fetal abnormality and Damage Preimplantation Genetic Diagnosis Sep 17 4

5 Q05.9 Spina Bifida Q06.0- Q06.9 Other congenital malformations of spinal cord Q Q87.89 Marfan s syndrome Q90.0- Q99 Chromosomal abnormalities, not elsewhere classified R93.8 Abnormal findings on diagnostic imaging of other specified body structures Z13.89 Encounter for screening for other disorder Z14.1 Cystic fibrosis carrier Z14.8 Genetic carrier of other disease Z36 Encounter for antenatal screening of mother Z81.0 Family history of intellectual disabilities Z82.0 Family history of epilepsy and other diseases of the nervous system Z83.2 Family history of diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism Z Z83.49 Family history of other endocrine, nutritional, and metabolic diseases Z82.79 Family history of other congenital malformations, deformations and chromosomal abnormalities Z84.89 Family history of other specified conditions CPT Codes Tier 1 Molecular Pathology Procedures MGMT (0-6-methylguanine-DNA methyltransferase) (eg Tier 2 Molecular Pathology Procedures In situ hybridization, (FISH), per specimen; initial single probe stain procedure (Revised in 2015) Biopsy, oocyte polar body or embryo blastomere, microtechnique (for preimplantation genetic diagnosis); less than or equal to 5 embryos Biopsy, oocyte polar body or embryo blastomere, microtechnique (for preimplantation genetic diagnosis); greater than 5 embryos HCPCS Codes S3840 S3841 S3842 S3845 S3846 S3849 S3850 S3853 DNA analysis for germline mutations of the ret proto-oncogene for susceptibility to multiple endocrine neoplasia type 2 Genetic testing for retinoblastoma Genetic testing for von Hippel-Lindau disease Genetic testing for alpha-thalassemia Genetic testing for hemoglobin E beta-thalassemia Genetic testing for Niemann-Pick disease Genetic testing for sickle cell anemia Genetic testing for myotonic muscular dystrophy Scientific Rationale Update September 2016 Kushnir et al (2016) assessed effectiveness of preimplantation genetic screening (PGS) in fresh IVF cycles in a reanalysis of retrospective US national data. A total of 5,471 fresh autologous IVF cycles with PGS and 97,069 cycles without PGS, reported Preimplantation Genetic Diagnosis Sep 17 5

6 in to the Centers for Disease Control and Prevention. More PGS than non-pgs cycles reached ET (64.2% vs. 62.3%), suggesting favorable patient selection bias for patients using PGS. Nevertheless, live births rates per cycle start (25.2% vs. 28.8%) and per ET (39.3% vs. 46.2%) were significantly better in non- PGS cycles, whereas miscarriage rates were similar (13.7% vs. 13.9%). With a maternal age >37 years significantly more cycles in the PGS group reached ET (53.1% vs. 41.9%), suggesting a significant selection bias for more favorable patients in the PGS population. This bias rather than the PGS procedure may partially explain the observed improved live birth rate per cycle (17.7% vs. 12.7%) and lower miscarriage rate (16.8% vs. 26.0%) in the older PGS group. The authors concluded overall, PGS decreased chances of live birth in association with IVF. National improvements in live birth and miscarriage rates reported with PGS in older women are likely the consequence of favorable patient selection biases. Scientific Rationale Update September 2015 Girardet et al. (2015) completed a study that provides an overview of 10 years of experience of preimplantation genetic diagnosis (PGD) for cystic fibrosis (CF) in the author s center. Owing to the high allelic heterogeneity of CF transmembrane conductance regulator (CFTR) mutations a powerful universal test has been set up based on haplotyping eight short tandem repeats (STR) markers together with the major mutation p.phe508del. Of 142 couples requesting PGD for CF, 76 have been so far enrolled in the genetic work-up, and 53 had 114 PGD cycles performed. Twentynine cycles were canceled upon in vitro fertilization (IVF) treatment because of hyper- or hypostimulation. Of the remaining 85 cycles, a total of 493 embryos were biopsied and a genetic diagnosis was obtained in 463 (93.9%), of which 262 (without or with a single CF-causing mutation) were transferable. Twenty-eight clinical pregnancies were established, yielding a pregnancy rate per transfer of 30.8% in the group of seven couples with one member affected with CF, and 38.3% in the group of couples whose both members are carriers of a CF-causing mutation [including six couples with congenital bilateral absence of the vas deferens (CBAVD)]. So far, 25 children were born free of CF and no misdiagnosis was recorded. This test is applicable to 98% of couples at risk of transmitting CF. Scientific Rationale Update September 2012 Stem cell transplantation has significantly improved the prognosis for many life threatening diseases, (e.g., children affected with Fanconi's anemia). Identification of a disease-free embryo that is also HLA compatible to the affected child and can provide cord blood stem cells for transplantation will significantly improve the probability of survival of the affected sibling. PGD has been used successfully to identify HLA-compatible unaffected embryos to permit treatment of an affected sibling by cord blood transfusion or bone marrow transplantation. However, very few of the embryos tested (about 16 percent) will be both unaffected and an HLA match for the affected sibling. In addition, finding an HLA-matched donor is not always possible, especially for minorities. While autologous hematopoietic stem cells provide perfectly compatible tissue, this type of transplantation is not appropriate in many cases, due to the presence of the disease to be treated in the collected autologous stem cells. Each full sibling potential donor has only a 25 percent chance of being fully HLA-matched with a sibling who requires a transplant. Therefore, many patients do not have an HLAidentical relative. When a suitable related donor is not available, a search is conducted to identify a potential unrelated HLA-matched donor. Finding an appropriate donor through a national registry is a lengthy process that is not always Preimplantation Genetic Diagnosis Sep 17 6

7 successful, especially for individuals who are not of Northern European descent. As a result, many patients who might benefit from HCT are not afforded this opportunity, or die during the extended process of securing a donor. Harper et al. (2012) For the last 20 years, preimplantation genetic diagnosis (PGD) has been mostly performed on cleavage stage embryos after the biopsy of 1-2 cells and PCR and FISH have been used for the diagnosis. The main indications have been single gene disorders and inherited chromosome abnormalities. Preimplantation genetic screening (PGS) for aneuploidy is a technique that has used PGD technology to examine chromosomes in embryos from couples undergoing IVF with the aim of helping select the chromosomally 'best' embryo for transfer. It has been applied to patients of advanced maternal age, repeated implantation failure, repeated miscarriages and severe male factor infertility. Recent randomized controlled trials (RCTs) have shown that PGS performed on cleavage stage embryos for a variety of indications does not improve delivery rates. At the cleavage stage, the cells biopsied from the embryo are often not representative of the rest of the embryo due to chromosomal mosaicism. There has therefore been a move towards blastocyst and polar body biopsy, depending on the indication and regulations in specific countries (in some countries, biopsy of embryos is not allowed). Blastocyst biopsy has an added advantage as vitrification of blastocysts, even post biopsy, has been shown to be a very successful method of cryopreserving embryos. However, mosaicism is also observed in blastocysts. There have been dramatic changes in the method of diagnosing small numbers of cells for PGD. Both array-comparative genomic hybridisation and single nucleotide polymorphism arrays have been introduced clinically for PGD and PGS. For PGD, the use of SNP arrays brings with it ethical concerns as a large amount of genetic information will be available from each embryo. For PGS, RCTs need to be conducted using both array-cgh and SNP arrays to determine if either will result in an increase in delivery rates. Scientific Rationale Update October 2011 Colls et al. (2009) Preimplantation genetic diagnosis (PGD) for gender selection for non-medical reasons has been considered an unethical procedure by several authors and agencies in the Western society on the basis that it could disrupt the sex ratio, that it discriminates against women and that it leads to disposal of normal embryos of the non-desired gender. In this study, the analysis of a large series of PGD procedures for gender selection from a wide geographical area in the USA shows that, in general, there is no deviation in preference towards any specific gender except for a preference of males in some ethnic populations of Chinese, Indian and Middle Eastern origin that represent a small percentage of the US population. In cases where only normal embryos of the non-desired gender are available, 45.5% of the couples elect to cancel the transfer, while 54.5% of them are open to have embryos transferred of the non-desired gender, this fact being strongly linked to cultural and ethnic background of the parents. In addition this study adds some evidence to the proposition that, in couples with previous children of a given gender, there is no biological predisposition towards producing embryos of that same gender. El-Toukhy et al. (2010) completed a review to inform the clinician about the application, success rates and limitations of preimplantation genetic diagnosis (PGD) for hematologic disease to enable clinicians to offer couples with reproductive risk a realistic view of possible treatments. The history and ethics involved in performing PGD together with human leukocyte antigen (HLA) testing (PGD-H) to create matched siblings suitable for hematopoietic stem cell transplant (HSCT) are discussed. The greatest diagnostic hurdle in PGD is the paucity of molecular material Preimplantation Genetic Diagnosis Sep 17 7

8 in the single embryonic cell. PGD to exclude embryos carrying serious hematologic disease is a viable alternative to prenatal diagnosis for couples whom wish to avoid having affected children and for whom therapeutic termination of affected pregnancies is unacceptable. PGD is not available for all hematologic mutations, is expensive, time consuming and does not guarantee a pregnancy. PGD-H is more diagnostically and ethically challenging, especially when there is the time constraint of urgent provision of HLA-matched stem cells for a sick sibling. To date there is only a handful of reported cases of successful HSCT from siblings created by embryo selection. Pre-implantation genetic diagnosis (PGD) has been proposed as a method for selecting HLA-matched embryos in order to create a tissue matched child that can serve as a stem cell donor. After delivery of the HLA-matched baby, umbilical cord blood (UCB) cells can be collected and cryopreserved for transplantation to the sick sibling or the affected child. Using pre-implantation HLA typing to have a tissuematched child that can serve as a haematopoietic stem cell donor to save a loved one s life. This is generally known as the creation of saviour siblings. Haematopoietic stem cells are found in the umbilical cord blood, bone marrow and peripheral blood. Despite recent promising results of using stem cells from the umbilical cord blood of so called saviour siblings for curing patients with blood diseases and certain types of cancer, this method has been met with much opposition. Concerns related to the risks of preimplantation genetic diagnosis (PGD) for the child to be born, the intention to have a donor child, the limits that should be placed on what cells or organs can be used from the child and whether the recipient can be someone other than a sibling). Preimplantation tissue typing has been proposed as a method for creating a tissue matched child that can serve as a haematopoietic stem cell donor to save its sick sibling in need of a stem cell transplant. Despite recent promising results, many people have expressed their disapproval of this method. Scientific Rationale Update February 2011 Tay Sachs Disease Altaruscu et al. (2007) Preimplantation genetic diagnosis (PGD) for single gene defects is described for a family in which each parent is a carrier of both Tay-Sachs (TS) and Gaucher disease (GD). A multiplex fluorescent polymerase chain reaction protocol was developed that simultaneously amplified all four familial mutations and 10 informative microsatellite markers. In one PGD cycle, seven blastomeres were analysed, reaching a conclusive diagnosis in six out of seven embryos for TS and in five out of seven embryos for GD. Of the six diagnosed embryos, one was wild type for both TS and GD, and three were wild type for GD and carriers of TS. Two remaining embryos were compound heterozygotes for TS. Two transferable embryos developed into blastocysts (wt/wt and wt GD/carrier TS) and both were transferred on day 5. This single cycle of PGD resulted in a healthy live child. Allele drop-out (ADO) was observed in three of 34 reactions, yielding an 8% ADO rate. The occurrence of ADO in single cell analysis and undetected recombination events are primary causes of misdiagnosis in PGD and emphasize the need to use multiple polymorphic markers. So far as is known, this is the first report of concomitant PGD for two frequent Ashkenazi Jewish recessive disorders. Fragile X Syndrome Malcov et al. (2007) Fragile X syndrome is caused by a dynamic mutation in the FMR1 gene. Normal individuals have <55 CGG repeats in the 5 untranslated region, premutation carriers have repeats and a full mutation has >200 repeats. Preimplantation Genetic Diagnosis Sep 17 8

9 Female carriers are at risk of having affected offspring. A multiplex nested polymerase chain reaction protocol is described for preimplantation genetic diagnosis (PGD) of fragile X syndrome with simultaneous amplification of the CGG-repeat region, the Sry gene and several flanking polymorphic markers. The amplification efficiency was > or =96% for all loci. The allele dropout rate in heterozygotic females was 9% for the FMR1 CGG-repeat region and 5-10% for the polymorphic markers. Amplification failure for Sry occurred in 5% of single leukocytes isolated from males. PGD was performed in six patients who underwent 15 cycles. Results were confirmed in all cases by amniocentesis or chorionic villous sampling. Five clinical pregnancies were obtained (31% per cycle), four of which resulted in a normal delivery and one miscarried. This technique is associated with high efficiency and accuracy and may be used in carriers of full mutations and unstable high-order premutations. Giardet et al. (2008) Two multiplex PGD protocols were developed allowing the detection of the common homozygous deletion of the telomeric spinal muscular atrophy gene (SMN1), together with two microsatellites located on each side of SMN1. The molecular genetics laboratory of the university hospital in Montpellier. PATIENT(S): A couple who had already given birth to a child affected with SMA.) In vitro fertilization using intracytoplasmic sperm injection (ICSI) and blastomere biopsy. MAIN OUTCOME MEASURE(S): Improvement of PGD for SMA. Two different multiplex protocols were set up on 81 (multiplex A) and 64 single cells (multiplex B) from normal controls, affected patients, and individuals with homozygous SMN2 deletion. In one PGD cycle that used one of these protocols, two embryos were transferred, which resulted in the birth of a healthy baby. Analysis of microsatellite markers in addition to the SMN1 deletion allows the detection of contamination, the study of ploidy of the biopsied blastomeres, and the performance of an indirect genetic diagnosis, thereby increasing the reliability of the results. This PGD assay may be applied to all families with the common deletion of SMN1 and also to couples in whom one of the partners carries a small intragenic mutation in SMN1, identified in about 6% of affected individuals who do not lack both copies of SMN1. Shaw et al. (2008) Thirty-three members of 7 families participated in carrier test and disease detection of SMA. Prenatal genetic diagnosis was performed if both parents were carriers or any family members had SMA. DNA extracted from blood, chorionic villi and amniotic fluid was amplified and used for DHPLC. Twenty SMA carriers, seven SMA affected cases, and six normal individuals were identified. SMA status was demonstrated by genotyping and total copy number determinations of SMN1 and SMN2. Families 1-3 were classified as group one (SMA affecting previously born child). Group two, comprising families 4 and 5, had lost a child due to an unknown muscular disease. Group three (SMA-affected parent) comprised families 6 and 7; carrier testing was done. DHPLC prenatal genetic diagnosis was made in seven pregnancies, one in each family (affected, n=2; carrier, n=3; normal, n=2). Pregnancy was terminated for the two affected fetuses. The others were delivered uneventfully and SMA free. DHPLC prenatal diagnosis of SMA and determination of SMA status in adults is possible, and SMN1 and SMN2 copy numbers can be determined. Alpha-1-antitrypsin deficiency Alpha-1 antitrypsin (AAT) deficiency emphysema is an inherited disorder affecting approximately 100,000 Americans. Affected patients have little or no blood and tissue levels of AAT (also called alpha-1 protease inhibitor, alpha1-pi, or A1-PI), which protects the lung from destruction by enzymes in the lung that normally digest bacteria and other invaders. Unchecked, this enzyme progressively damages healthy Preimplantation Genetic Diagnosis Sep 17 9

10 lung tissue leading to decreased lung function and emphysema. The prognosis for patients with high-risk phenotypes for AAT deficiency emphysema is poor although symptomatic treatments and more definitive lung surgery are options. Cystic Fibrosis Norton et al. (2008) Recent advances in genetic technology have substantial implications for prenatal screening and diagnostic testing. The past year has also seen important changes in recommendations surrounding the genetic counseling that occurs in the provision of such testing. Multiple screening tests for single gene disorders, chromosomal abnormalities, and structural birth defects are now routinely offered to all pregnant women. Ethnicity-based screening for single gene disorders includes Tay Sachs disease, cystic fibrosis, and hemoglobinopathies. Recent discussions have involved, not only additional disorders that warrant screening, but a re-evaluation of the paradigm of selecting disorders for population-based screening. Testing for chromosomal abnormalities has seen the introduction of first-trimester screening, as well as strategies to improve detection through sequential testing. Changes in recommendations for screening compared with diagnostic testing, and a move away from maternal age-based dichotomizing of testing, have had major implications for provision of genetic counseling by providers of prenatal care. Advances in genetic testing have resulted in tremendous benefits to patients, and challenges to providers. New approaches to education and counseling are needed to assure that all patients receive a complete and balanced review of their prenatal genetic-testing options. Fanconi Anemia Modern Ashkenazi Jewish (AJ) populations (Ashkenazic Jews or Ashkenazim) descended from the Jewish communities of Germany, Poland, Austria, and Eastern Europe. Approximately 90% of the 5.7 million individuals of Jewish descent in the USA today are of AJ origin. Certain childhood-onset autosomal recessive genetic disorders are more common among the AJ community including Tay-Sachs disease, Canavan disease, familial dysautonomia, Bloom syndrome, Fanconi anemia group C, Gaucher disease, mucolipidosis type IV, Niemann-Pick disease type 1A, cystic fibrosis, and primary dystonia type 1 (torsion dystonia). Over the last few decades, the molecular basis of these diseases has been elucidated providing the tools and the opportunity to perform preconceptual carrier screening for these disorders in this ethnic group. The relatively homogeneous genetic make-up of the AJ population has resulted in there being a relatively limited number of disease-causing sequence variants accounting for the majority of cases of each disease which has allowed for the development of screening panels with a high level of sensitivity and specificity for the AJ population. As a result of the autosomal recessive mode of inheritance for these disorders, if both members of a couple are carriers, they have a 25% chance of having a child with the disorder. Fifteen autosomal recessive disorders were reviewed in order to determine whether or not they should be included in an AJ screening panel. The 15 disorders are: alpha-1-antitrypsin deficiency (AAD), Bloom syndrome (BLM), Canavan disease (CD), CF, deafness neurosensory autosomal recessive 1 (DFNB1), FD, familial hyperinsulinism (FHI), Fanconi anemia type C (FAC), Gaucher disease type 1 (GD), glycogen storage disease type 1A (GSD), maple syrup urine disease type 1b (MSUD), mucolipidosis type IV (MLIV), Niemann-Pick disease types A and B (NPDA&B), nonclassical congenital adrenal hyperplasia (NCAH), and Tay-Sachs disease (TSD). There is controversy, however, surrounding which diseases should be included in such screening panels. While serious, generally fatal disorders such as Tay-Sachs disease and Canavan disease are clear candidates Preimplantation Genetic Diagnosis Sep 17 10

11 for screening; the argument is not as clear for disorders with variable clinical presentation and reduced penetrance such as Gaucher disease or primary dystonia. Fares et al. (2008) completed a study, with a database containing the results of 410 genotyping assays was screened. Ten thousand seventy eight nonselected healthy members of the AJ population were tested for carrier status for the following diseases; Gaucher disease (GD), cystic fibrosis (CF), Familial dysautonomia (FD), Alpha 1 antitrypsin (A1AT), Mucolipidosis type 4 (ML4), Fanconi anemia type C (FAC), Canavan disease (CD), Neimann-Pick type 4 (NP) and Bloom syndrome (BLM). The results demonstrated that 635 members were carriers of one mutation and 30 members were found to be carriers of two mutations in the different genes related to the development of the above mentioned diseases. GD was found to have the highest carrier frequency (1:17) followed by CF (1:23), FD (1:29), A1AT (1:65), ML4 (1:67) and FAC (1:77). The carrier frequency of CD, NP and BLM was 1:82, 1:103 and 1:157, respectively. The frequency of the disease-causing mutations screened routinely among the AJ population indicated that there are rare mutations with very low frequencies. The screening policy of the disease-causing mutations should be reevaluated and mutations with a high frequency should be screened, while rare mutations with a lower frequency may be tested in partners of carriers. Hemophilia A for Hemophilia A/Factor 8 Deficiency Laurie et al. (2010) Preimplantation genetic diagnosis (PGD) is an option for couples at risk of having a child with hemophilia A (HA). Although many clinics offer PGD for HA by gender selection, an approach that detects the presence of the underlying F8 mutation has several advantages. The objection was to develop and validate analysis protocols combining indirect and direct methods for identifying F8 mutations in single cells, and to apply these protocols clinically for PGD. A panel of microsatellite markers in linkage disequilibrium with F8 were validated for single-cell multiplex polymerase chain reaction. For point mutations, a primer extension genotyping assay was included in the multiplex. Amplification efficiency was evaluated using buccal cells and blastomeres. Four clinical PGD analyses were performed, for two families. Results: Across all validation experiments and the clinical PGD cases, approximately 80% of cells were successfully genotyped. Following one of the PGD cycles, healthy twins were born to a woman who carries the F8 intron 22 inversion. The PGD analysis for the other family was complicated by possible germline mosaicism associated with a de novo F8 mutation, and no pregnancy was achieved. Conclusions: PGD for the F8 intron 22 inversion using microsatellite linkage analysis was validated by the birth of healthy twins to one of the couples. The other family's situation highlighted the complexities associated with de novo mutations, and possible germline mosaicism. As many cases of HA result from de novo mutations, these factors must be considered when assessing the reproductive options for such families. Per the American Congress of Obstetricians and Gynecologists (ACOG). ACOG Committee Opinion. Number 430 March Preimplantation Genetic Screening for Aneuploidy states the following: Preimplantation genetic screening differs from preimplantation genetic diagnosis for single gene disorders and was introduced for the detection of chromosomal aneuploidy. Current data does not support a recommendation for preimplantation genetic screening for aneuploidy using fluorescence in situ hybridization solely because of maternal age. Also, preimplantation genetic screening for aneuploidy does not improve in vitro fertilization success rates and may be detrimental. At this Preimplantation Genetic Diagnosis Sep 17 11

12 time there are no data to support preimplantation genetic screening for recurrent unexplained miscarriage and recurrent implantation failures; its use for these indications should be restricted to research studies with appropriate informed consent. Preimplantation genetic screening differs from preimplantation genetic diagnosis (PGD) for single gene disorders. In order to perform genetic testing for single gene disorders, PGD was introduced in 1990 as a component of in vitro fertilization programs. Such testing allows the identification and transfer of embryos unaffected by the disorder in question and may avoid the need for pregnancy termination. Assessment of polar bodies as well as single blastomeres from cleavage stage embryos has been reported, although the latter is the approach most widely practiced. Preimplantation genetic diagnosis has become a standard method of testing for single gene disorders, and there have been no reports to suggest adverse postnatal effects of the technology. Preimplantation genetic diagnosis has been used for diagnosis of translocations and single-gene disorders, such as cystic fibrosis, X- linked recessive conditions, and inherited mutations, which increase one s risk of developing cancer. In contrast, in the latter half of the 1990s, preimplantation genetic screening was introduced for the detection of chromosomal aneuploidy (2 4). Aneuploidy leads to increased pregnancy loss with increasing maternal age and also was thought to be a major cause of recurrent pregnancy loss in patients using assisted reproductive technologies. However, when compared with the molecular diagnostics available for PGD of single gene disorders, the current technologies available for preimplantation genetic screening for aneuploidy are more limited. Preimplantation genetic screening using fluorescence in situ hybridization is constrained by the technical limitations of assessing the numerical status of each chromosome. Typically assessed are the chromosome abnormalities associated with common aneuploidies found in spontaneous abortion material, and because of this, and other limitations noted in this Committee Opinion, a significant false-negative rate exists. Therefore, this form of testing should be considered a screening test, and not a diagnostic test, as is the case for PGD for single gene disorders. Because preimplantation chromosome assessment tests a single cell, there are certain limitations: Testing a single cell prohibits confirmation of results. There is a limit to the number of tests that can be done with a single cell. Embryo mosaicism of normal and aneuploid cell lines may not be clinically significant. Guidelines for counseling on limitations of this screening have been developed by the American Society for Reproductive Medicine. Recommendations of ACOG: Current data does not support a recommendation for preimplantation genetic screening for aneuploidy using fluorescence in situ hybridization solely because of maternal age. Preimplantation genetic screening for aneuploidy does not improve in vitro fertilization success rates and may be detrimental. At this time there are no data to support preimplantation genetic screening for recurrent unexplained miscarriage and recurrent implantation failures; its use for these indications should be restricted to research studies with appropriate informed consent. Preimplantation Genetic Diagnosis Sep 17 12

13 Scientific Rationale Initial With recent advances in genetics, there are a good number of inherited disorders, which can now be diagnosed at a molecular level. For couples who are carriers or affected by any of a variety of genetic diseases and are at high risk for transmitting it to their offspring, it is currently possible to detect the disorder during pregnancy. This is done by one of two approaches: chorionic villus sampling in the first trimester or amniocentesis in the second trimester. However the couples have the dilemma of whether or not to terminate the pregnancy if the genetic abnormality is present. In some cases this may also not be a viable option for religious or moral reasons. An alternative would then be to diagnose the condition in embryos before the pregnancy is established. Only the unaffected embryos would then be transferred to the uterus. This new technique that combines advances in molecular genetics and assisted reproductive technologies is referred to as preimplantation genetic diagnosis (PGD). It does not involve the manipulation of genes in embryos; rather, it selects among embryos. PGD involves several steps: the creation of an embryo via IVF; the removal of one or two cells from the embryo; the genetic testing of these cells for specific genetic conditions; and the subsequent transfer of unaffected embryos to a woman s uterus. Currently, IVF is the only available technique for obtaining an embryo in the very early stages of development. One to two single cells, blastomeres, are removed from early cleavage stage embryos (6 8-cell stage) at approximately 3 days' postfertilization. The blastomere contains genetic material that can be analyzed to identify three categories of disorders, including aneuploidy and structural chromosomal abnormalities, single-gene disorders, and X-linked disorders. Although couples with a high risk of transmitting a genetic defect to their offspring may have normal fertility, they would need to go through the IVF procedure to provide embryos for screening. Fertility specialists can use the results of this analysis to select only mutation-free embryos for implantation into the mother's uterus, hence preventing the physical and psychological trauma associated with possible termination. Clinical and practical considerations include that the embryo must be healthy enough to survive the procedure. It is estimated that only 2.5% of eggs collected will form a viable unaffected pregnancy. Maternal age is an important factor, particularly for aneuploidy screening in women older than 35 years of age, as this increases the likelihood of finding a chromosomal abnormality and decreases the success rate of IVF. With PGD, couples are much more likely to have healthy babies. Although PGD has been practiced for years, only a few specialized centers worldwide offer this procedure. PGD should be offered for 3 major groups of disease, including (1) sex-linked disorders, (2) single gene defects, and (3) chromosomal disorders. X-linked diseases are passed to the child through a mother who is a carrier. They are passed by an abnormal X chromosome and manifest in sons, who do not inherit the normal X chromosome from the father. Affected fathers have sons who are not affected, and their daughters have a 50% risk of being carriers if the mother is healthy. Sex-linked recessive disorders include hemophilia, fragile X syndrome, most of the neuromuscular dystrophies (currently > 900 neuromuscular dystrophies are known), and hundreds of other diseases. Sex-linked dominant disorders include Rett syndrome, incontinentia pigmenti, pseudohyperparathyroidism, and vitamin D resistant rickets. This genetic test is currently available to couples whose offspring are at a high risk (25-50%) for a specific genetic condition due to one or both parents being carriers or affected by the disease. Also the genetic code associated Preimplantation Genetic Diagnosis Sep 17 13

14 with the condition must be known in order to allow diagnosis. Currently, it is not feasible to routinely screen women at lower risks, such as women over age 35 for Downs Syndrome, since the means of establishing a pregnancy is with the help of IVF. PGD is used to identify single gene defects such as cystic fibrosis, Tay-Sachs disease, sickle cell anemia, and Huntington disease. In such diseases, the molecular abnormality is detectable with molecular techniques using PCR amplification of DNA from a single cell. Although progress has been made, some single gene defects have a wide variety of rare mutations (e.g., cystic fibrosis has approximately 1000 known mutations). Only 25 of these mutations are currently routinely tested. Because most of these rare mutations are not routinely tested, a parent without any clinical manifestations of cystic fibrosis could be a carrier. This allows the possibility for a parent carrying a rare mutation gene to be tested as negative but still have the ability to pass on the mutant cystic fibrosis gene. The last group includes chromosomal disorders in which a variety of chromosomal rearrangements, including translocations, inversions, and deletions, can be detected using FISH. Some parents may have never achieved a viable pregnancy without using PGD because previous conceptions resulted in chromosomally unbalanced embryos and were spontaneously miscarried. The risk of aneuploidy in children increases as women age. The chromosomes in the egg are less likely to divide properly, leading to an extra or missing chromosome in the embryo. The rate of aneuploidy in embryos is greater than 20% in mothers aged years and is nearly 40% in mothers aged 40 years or older. The rate of aneuploidy in children is % in mothers aged years and is % in mothers older than 40 years. The difference in percentages between affected embryos and live births is due to the fact that an embryo with aneuploidy is less likely to be carried to term and will most likely be miscarried, some even before pregnancy is suspected or confirmed. Therefore, using PGD to determine the chromosomal makeup of embryos increases the chance of a healthy pregnancy and reduces the number of pregnancy losses and affected offspring with so-called serious inherited disorders such as Tay Sachs; Trisomies 13, 18, and 21; cystic fibrosis; muscular dystrophy; Huntington disease; Lesch-Nyhan; and neurofibromatosis. PDG is also presently has much wider indications than prenatal diagnosis, including common diseases with genetic predisposition and preimplantation human leukocyte antigen typing, with the purpose of establishing potential donor progeny for stem cell treatment of siblings. Many hundreds of apparently healthy, unaffected children have been born after preimplantation genetic diagnosis, presenting evidence of its accuracy, reliability and safety. Preimplantation genetic diagnosis appears to be of special value for avoiding age-related aneuploidies in patients of advanced reproductive age, improving reproductive outcome, particularly obvious from their reproductive history, and is presently an extremely attractive option for carriers of balanced translocations to have unaffected children of their own. Many people fear that PGD will be used to select a child of a preferred sex. PGD could also be used in attempts to select a future child's cosmetic, behavioral, and other non-disease traits. However, the genetic laws of independent assortment make it difficult for PGD to be used for any traits that depend on two or more genes. Thus, PGD provides an alternative to germline modification as a way to prevent the births of children with serious genetic diseases, most of which are single-gene disorders, but does not open the door to escalating and species-altering applications. Preimplantation Genetic Diagnosis Sep 17 14

15 Research continues in the area of PGD. There is now a rapidly growing list of disorders for which PGD has been applied successfully, including cystic fibrosis, Tay- Sachs disease, hemophilia A and B, retinitis pigmentosa, numerous inborn errors of metabolism, fragile X syndrome, Duchenne muscular dystrophy, and chromosomal abnormalities, to name a few. The risks of PGD are similar to risks for IVF, namely multiple-fetal pregnancies and the twofold increased risk for major birth defects and low birth weight. Preliminary studies show no increased risk for spontaneous abortions. The data from long-term follow-up of children conceived after PGD, however, have yet to be collected. Review History October 2005 November 2006 November 2007 February 2011 October 2011 September 2012 September 2013 September 2014 September 2015 September 2016 September 2017 Medical Advisory Council initial approval Medical Advisory Council - no changes Update no revisions Update. Added Medicare Table. No revisions. Update - no revisions Update no revisions Update no revisions. Code updates Update no revisions. Code updates. Update no revisions. Code updates. Update no revisions. Code updates Update no revisions. Code updates This policy is based on the following evidence-based guidelines: 1. American College of Obstetricians and Gynecologists, American College of Medical Genetics: Preconception and Prenatal Carrier Screening for Cystic Fibrosis: Clinical and Laboratory Guidelines. Washington, DC; American College of Obstetrics and Gynecology; October, American Society for Reproductive Medicine, Society for Assisted Reproductive Technology: A practice committee report: Preimplantation genetic diagnosis. Birmingham, Ala. June National Ethics Committee on Assisted Human Reproduction. Guidelines for Preimplantation Genetic Diagnosis in New Zealand. Consultation Document. September Thornhill AR, dedie-smulders CE, Geraedts JP, et al. European Society of Human Reproduction and Embryology (ESHRE) PGD Consortium. Best practice guidelines for clinical preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS) Available at: 5. Developments in infertility therapy. Diagnosis of genetic disease in embryos. Australian Family Physician Vol. 34, No. 3, March International Working Group on Preimplantation Genetics, International Congress of Human Genetics: Preimplantation Genetic Diagnosis: Experience of Three Thousand Cycles. Report of the 11th Annual Meeting of International Working Group on Preimplantation Genetics, in association with 10th International Congress of Human Genetics. Vienna, Austria; May, American Society For Reproductive Medicine. Preimplantation Genetic Diagnosis Fact Sheet. 12/ Preimplantation genetic testing: a Practice Committee opinion. Practice Committee of the Society for Assisted Reproductive Technology; Practice Committee of the American Society for Reproductive Medicine. Fertil Steril 2007;88: Preimplantation Genetic Diagnosis Sep 17 15

16 9. Hayes. Medical Technology Directory. Genetic Testing for Tay-Sachs Disease. Updated March 6, Archived November 12, Hayes. Genetic Test Overview. Fragile X Syndrome (FMR1) for Mental Retardation. August 7, 2008, Updated August 1, Archived July 13, Hayes. Genetic Test Overview. Y Chromosome Microdeletion Analysis for Male Infertility. November 14, 2008, Updated December 6, Archived December 14, American Congress of Obstetricians and Gynecologists (ACOG). ACOG Committee Opinion. Number 430. March Preimplantation Genetic Screening for Aneuploidy. Reaffirmed Hayes. Genetic Test Overview. Spinal Muscular Atrophy (SMA) for Progressive Muscle Weakness. January 23, 2009, Updated January 31, Updated January 17, Archived February 23, Hayes. Genetic Test Evaluation Overview. Ashkenazi Jewish Genetic Screening Panel for Risk Assessment. February 18, 2009, Updated February 15, Updated February 13, Archived March 18, Hayes. Genetic Test Overview. COL1A1 and COL1A2 Testing for Osteogenesis Imperfecta Types I to IV. February 20, 2009, Updated February 14, Archived March 20, Hayes. Genetic Test Overview. GTE Report: Charcot-Marie-Tooth Type 1A (PMP22). Published: August 5, Updated Aug 23, 2010, Updated July 31, Archived June 30, Hayes. Genetic Test Overview. Spinocerebellar Ataxia Type 1 (SCA1) for Movement Disorders. March 3, 2010, Updated February 10, Archived March 9, Hayes. Genetic Test Overview. GTE Report: Myotonic Dystrophy Types 1 and 2 Published: March 9, Latest Update Search: Mar 31, 2010, Updated March 2, Archived April 9, Hayes. Genetic Test Overview. Spinocerebellar Ataxia Type 2 (SCA2) for Movement Disorders. March 3, 2010, Updated February 10, Archived March 23, Hayes. Genetic Test Overview. Spinocerebellar Ataxia Type 3 (SCA3; Machado- Joseph Disease) for Movement Disorders. March 3, 2010, Updated February 13, Archived February 27, Hayes. Genetic Test Overview. Spinocerebellar Ataxia Type 6 (SCA6) for Movement Disorders. March 31, 2010, Updated March 13, Archived April 11, Hayes. Genetic Test Overview. Spinocerebellar Ataxia Type 7 (SCA7) Movement Disorder. April 29, 2010, Updated April 18, Archived May 29, Hayes. Genetic Test Overview. GTE Report: Huntington Chorea/Disease (HD) for Diagnostic, Predictive, and Prenatal or Preimplantation Genetic Diagnosis Purposes. Published: April 29, Updated May 6, 2010, Updated April 25, Archived May 29, Hayes. Genetic Test Overview. Comparative Genomic Hybridization (CGH) Microarray for Chromosomal Imbalance. April 12, 2010, Updated February 7, Updated May 22, Updated May 19, Hayes. Genetic Test Overview. Marfan Syndrome. May 7, 2010, Updated April 27, Archived May 2, Hayes. Genetic Test Overview. Spinocerebellar Ataxia Type 12 (SCA12) for Movement Disorders. June 15, 2010, Updated June 2, Archived Hayes. Genetic Test Overview. Spinocerebellar Ataxia Type 17 (SCA17) for Movement Disorders. June 17, 2010, Updated May 22, Archived July 25, 2014 Preimplantation Genetic Diagnosis Sep 17 16

PATIENT EDUCATION. carrier screening INFORMATION

PATIENT EDUCATION. carrier screening INFORMATION PATIENT EDUCATION carrier screening INFORMATION carrier screening AT A GLANCE Why is carrier screening recommended? Carrier screening is one of many tests that can help provide information to you and your

More information

Medical Policy Preimplantation Genetic Testing

Medical Policy Preimplantation Genetic Testing Medical Policy Preimplantation Genetic Testing Document Number: 004 Commercial* and Connector/ Qualified Health Plans Authorization required X No notification or authorization Not covered * Not all commercial

More information

Original Policy Date

Original Policy Date MP 2.04.77 Preimplantation Genetic Testing Medical Policy Section OB/Gyn/Reproduction Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to

More information

ETHICAL ISSUES IN REPRODUCTIVE MEDICINE

ETHICAL ISSUES IN REPRODUCTIVE MEDICINE ETHICAL ISSUES IN REPRODUCTIVE MEDICINE Medicine was, in its history, first of all curative, then preventive and finally predictive, whereas today the order is reversed: initially predictive, then preventive

More information

Preimplantation Genetic Testing

Preimplantation Genetic Testing Protocol Preimplantation Genetic Testing (40205) Medical Benefit Effective Date: 01/01/14 Next Review Date: 09/14 Preauthorization No Review Dates: 09/11, 09/12, 09/13 The following Protocol contains medical

More information

MEDICAL POLICY SUBJECT: PRENATAL GENETIC TESTING. POLICY NUMBER: CATEGORY: Laboratory Test

MEDICAL POLICY SUBJECT: PRENATAL GENETIC TESTING. POLICY NUMBER: CATEGORY: Laboratory Test MEDICAL POLICY SUBJECT: PRENATAL GENETIC TESTING PAGE: 1 OF: 9 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including

More information

Original Policy Date

Original Policy Date MP 2.04.76 Genetic Counseling Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Created Local Policy/ 12:2013 Return to Medical Policy Index Disclaimer

More information

A Lawyer s Perspective on Genetic Screening Performed by Cryobanks

A Lawyer s Perspective on Genetic Screening Performed by Cryobanks A Lawyer s Perspective on Genetic Screening Performed by Cryobanks As a lawyer practicing in the area of sperm bank litigation, I have, unfortunately, represented too many couples that conceived a child

More information

An Update on PGD: Where we are today

An Update on PGD: Where we are today An Update on PGD: Where we are today Joyce Harper UCL Centre for PG&D and CRGH Institute for Womens Health University College London Overview What is PGD/PGS How we do it Disadvantages and advantages Future

More information

A Stepwise Approach to Embryo Selection and Implantation Success

A Stepwise Approach to Embryo Selection and Implantation Success Precise Genetic Carrier Screening An Overview A Stepwise Approach to Embryo Selection and Implantation Success Put today s most advanced genetic screening technology to work for you and your family s future.

More information

Should Universal Carrier Screening be Universal?

Should Universal Carrier Screening be Universal? Should Universal Carrier Screening be Universal? Disclosures Research funding from Natera Mary E Norton MD University of California, San Francisco Antepartum and Intrapartum Management June 15, 2017 Burden

More information

Article Preimplantation diagnosis and HLA typing for haemoglobin disorders

Article Preimplantation diagnosis and HLA typing for haemoglobin disorders RBMOnline - Vol 11. No 3. 2005 362-370 Reproductive BioMedicine Online; www.rbmonline.com/article/1853 on web 20 July 2005 Article Preimplantation diagnosis and HLA typing for haemoglobin disorders Dr

More information

GENETIC TESTING AND COUNSELING FOR HERITABLE DISORDERS

GENETIC TESTING AND COUNSELING FOR HERITABLE DISORDERS Status Active Medical and Behavioral Health Policy Section: Laboratory Policy Number: VI-09 Effective Date: 03/17/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members

More information

Articles Polar body-based preimplantation diagnosis for X-linked disorders

Articles Polar body-based preimplantation diagnosis for X-linked disorders RBMOnline - Vol 4. No 1. 38 42 Reproductive BioMedicine Online; www.rbmonline.com/article/384 on web 20 November 2001 Articles Polar body-based preimplantation diagnosis for X-linked disorders Dr Yury

More information

Genomics and Genetics in Healthcare. By Mary Knutson, RN, MSN

Genomics and Genetics in Healthcare. By Mary Knutson, RN, MSN Genomics and Genetics in Healthcare By Mary Knutson, RN, MSN Clinical Objectives Understand the importance of genomics to provide effective nursing care Integrate genetic knowledge and skills into nursing

More information

Agro/Ansc/Bio/Gene/Hort 305 Fall, 2017 MEDICAL GENETICS AND CANCER Chpt 24, Genetics by Brooker (lecture outline) #17

Agro/Ansc/Bio/Gene/Hort 305 Fall, 2017 MEDICAL GENETICS AND CANCER Chpt 24, Genetics by Brooker (lecture outline) #17 Agro/Ansc/Bio/Gene/Hort 305 Fall, 2017 MEDICAL GENETICS AND CANCER Chpt 24, Genetics by Brooker (lecture outline) #17 INTRODUCTION - Our genes underlie every aspect of human health, both in function and

More information

MULTIPLE CHOICE QUESTIONS

MULTIPLE CHOICE QUESTIONS SHORT ANSWER QUESTIONS-Please type your awesome answers on a separate sheet of paper. 1. What is an X-linked inheritance pattern? Use a specific example to explain the role of the father and mother in

More information

Reproductive Technology, Genetic Testing, and Gene Therapy

Reproductive Technology, Genetic Testing, and Gene Therapy Michael Cummings Chapter 16 Reproductive Technology, Genetic Testing, and Gene Therapy David Reisman University of South Carolina 16.1 Infertility Is a Common Problem In the US, about 13% of all couples

More information

Pre-Implantation Genetic Diagnosis. Bradley Kalinsky, MD Amanda Kalinsky, RN, BSN

Pre-Implantation Genetic Diagnosis. Bradley Kalinsky, MD Amanda Kalinsky, RN, BSN Pre-Implantation Genetic Diagnosis Bradley Kalinsky, MD Amanda Kalinsky, RN, BSN Our Clinical Vignette A young couple in the mid-to-late twenties presents to your clinic to discuss having children. The

More information

Pre-Implantation Genetic Diagnosis. Bradley Kalinsky, MD Amanda Kalinsky, RN, BSN

Pre-Implantation Genetic Diagnosis. Bradley Kalinsky, MD Amanda Kalinsky, RN, BSN Pre-Implantation Genetic Diagnosis Bradley Kalinsky, MD Amanda Kalinsky, RN, BSN Our Clinical Vignette A young couple in the mid-to-late twenties presents to your clinic to discuss having children. The

More information

Preimplantation Genetic Diagnosis (PGD) in Western Australia

Preimplantation Genetic Diagnosis (PGD) in Western Australia Preimplantation Genetic Diagnosis (PGD) in Western Australia Human somatic cells have 46 chromosomes each, made up of the 23 chromosomes provided by the egg and the sperm cell from each parent. Each chromosome

More information

Problem Challenge Need. Solution Innovation Invention

Problem Challenge Need. Solution Innovation Invention Problem Challenge Need Solution Innovation Invention Tubal Infertility In-vitro Fertilisation Steptoe and Edwards Birth after the reimplantation of a human embryo. Lancet 1978 Louise Brown, 25. Juli 1978

More information

Abstract. Introduction. RBMOnline - Vol 8. No Reproductive BioMedicine Online; on web 10 December 2003

Abstract. Introduction. RBMOnline - Vol 8. No Reproductive BioMedicine Online;   on web 10 December 2003 RBMOnline - Vol 8. No 2. 224-228 Reproductive BioMedicine Online; www.rbmonline.com/article/1133 on web 10 December 2003 Article Preimplantation genetic diagnosis for early-onset torsion dystonia Dr Svetlana

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Invasive Prenatal (Fetal) Diagnostic Testing File Name: Origination: Last CAP Review: Next CAP Review: Last Review: invasive_prenatal_(fetal)_diagnostic_testing 12/2014 3/2018

More information

PGD: FROM DIAGNOSIS TO THERAPY

PGD: FROM DIAGNOSIS TO THERAPY PGD: FROM DIAGNOSIS TO THERAPY MC Magli, L. Gianaroli Reproductive Medicine Unit - Via Mazzini, 2-438 Bologna www.sismer.it Since the birth of the first baby conceived using IVF techniques in 978 over

More information

24-Feb-15. Learning objectives. Family genetics: The future??? The traditional genetics. Genetics and reproduction in early 2015.

24-Feb-15. Learning objectives. Family genetics: The future??? The traditional genetics. Genetics and reproduction in early 2015. Learning objectives Family genetics: The future??? Peter Illingworth Medical Director IVFAustralia Understand how genetic problems may affect successful conception Consider the possible conditions and

More information

Date of birth: / / Date of birth: / /

Date of birth: / / Date of birth: / / Name (Female): Partner s name: Date of birth: / / Date of birth: / / IVF Number: Background Information An individual s genetic information is packaged into strings of DNA called chromosomes. Normal human

More information

EVOLVE CARRIER GENETIC SCREENS. Better health for generations to come! Be Proactive. SCREEN TODAY. PROTECT TOMORROW.

EVOLVE CARRIER GENETIC SCREENS. Better health for generations to come! Be Proactive. SCREEN TODAY. PROTECT TOMORROW. EVOLVE CARRIER GENETIC SCREENS Better health for generations to come! Be Proactive. SCREEN TODAY. PROTECT TOMORROW. PROTECT THE HEALTH OF YOUR FUTURE CHILDREN BY KNOWING YOUR GENETIC RISKS, TODAY! Carrier

More information

EVOLVE GENETIC FERTILITY SCREENS

EVOLVE GENETIC FERTILITY SCREENS LEADERS IN GENETIC FERTILITY SCREENING TM FOR MEN & WOMEN EVOLVE GENETIC FERTILITY SCREENS The most advanced and comprehensive pre-ivf fertility screens on the market today. SCREEN TODAY. PROTECT TOMORROW.

More information

Genetic Testing and Policies ASLME Public Health Conference September 14, 2010

Genetic Testing and Policies ASLME Public Health Conference September 14, 2010 Genetic Testing and Policies ASLME Public Health Conference September 14, 2010 Judith Daar Associate Dean, Whittier Law School Clinical Professor, UCI College of Medicine Genetics and Society Genetic

More information

Date of birth: / / Date of birth: / /

Date of birth: / / Date of birth: / / Name (Female): Partner s name: Date of birth: / / Date of birth: / / IVF Number: Background Information An individual s genetic information is packaged into strings of DNA called chromosomes. Normal human

More information

Preimplantation Genetic Testing Where are we going? Genomics Clinical Medicine Symposium Sept 29,2012 Jason Flanagan, MS,CGC

Preimplantation Genetic Testing Where are we going? Genomics Clinical Medicine Symposium Sept 29,2012 Jason Flanagan, MS,CGC Preimplantation Genetic Testing Where are we going? Genomics Clinical Medicine Symposium Sept 29,2012 Jason Flanagan, MS,CGC Overview Discuss what PGD and PGS are Pt examples What we have learned Where

More information

C H A P T E R Molecular Genetics Techniques for Preimplantation Genetic Diagnosis

C H A P T E R Molecular Genetics Techniques for Preimplantation Genetic Diagnosis Author, please provide citation of references 82, 83 in the text C H A P T E R Molecular Genetics 16 Techniques for Preimplantation Genetic Diagnosis Francesco Fiorentino, Gayle M Jones Introduction HISTORICAL

More information

PATIENT CONSENT FORM Preimplantation Genetic Screening (PGS) 24 Chromosome Aneuploidy and Translocation Screening with acgh

PATIENT CONSENT FORM Preimplantation Genetic Screening (PGS) 24 Chromosome Aneuploidy and Translocation Screening with acgh PREIMPLANTATION GENETIC SCREENING FOR ANEUPLOIDY SCREENING INTRODUCTION Preimplantation genetic screening (PGS) is used in conjunction with in-vitro fertilization (IVF) to screen embryos for numerical

More information

EVOLVE FERTILITY GENETIC SCREENS

EVOLVE FERTILITY GENETIC SCREENS LEADERS IN GENETIC FERTILITY SCREENING TM FOR MEN & WOMEN EVOLVE FERTILITY GENETIC SCREENS The most advanced and comprehensive fertility genetic screens on the market today. SCREEN TODAY. PROTECT TOMORROW.

More information

Single Gene (Monogenic) Disorders. Mendelian Inheritance: Definitions. Mendelian Inheritance: Definitions

Single Gene (Monogenic) Disorders. Mendelian Inheritance: Definitions. Mendelian Inheritance: Definitions Single Gene (Monogenic) Disorders Mendelian Inheritance: Definitions A genetic locus is a specific position or location on a chromosome. Frequently, locus is used to refer to a specific gene. Alleles are

More information

Expanded Carrier Screening: What s Best?

Expanded Carrier Screening: What s Best? Expanded Carrier Screening: What s Best? James D Goldberg, MD September 17, 2017 Disclosures James D. Goldberg, M.D. Chief Medical Officer, Counsyl 3 Learning Objectives Guidelines Data Design Practice

More information

The Ethical Implications of Preimplantation Genetic Diagnosis (PGD)

The Ethical Implications of Preimplantation Genetic Diagnosis (PGD) The Ethical Implications of Preimplantation Genetic Diagnosis (PGD) "The great challenge to mankind today is not only how to create, but to know when to stop creating." Lord Emmanuel Jacobvitz, former

More information

PGS & PGD. Preimplantation Genetic Screening Preimplantation Genetic Diagnosis

PGS & PGD. Preimplantation Genetic Screening Preimplantation Genetic Diagnosis 1 PGS & PGD Preimplantation Genetic Screening Preimplantation Genetic Diagnosis OUR MISSION OUR MISSION CooperGenomics unites pioneering leaders in reproductive genetics, Reprogenetics, Recombine, and

More information

Article Pre-embryonic diagnosis for Sandhoff disease

Article Pre-embryonic diagnosis for Sandhoff disease RBMOnline - Vol 12. No 3. 2006 328-333 Reproductive BioMedicine Online; www.rbmonline.com/article/2100 on web 9 January 2006 Article Pre-embryonic diagnosis for Sandhoff disease Dr Anver Kuliev received

More information

Human inherited diseases

Human inherited diseases Human inherited diseases A genetic disorder that is caused by abnormality in an individual's DNA. Abnormalities can range from small mutation in a single gene to the addition or subtraction of a whole

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Carrier Screening for Genetic Disease File Name: Origination: Last CAP Review: Next CAP Review: Last Review: carrier_screening_for_genetic_disease 12/2013 7/2017 7/2018 7/2017

More information

Genetic Diseases. SCPA202: Basic Pathology

Genetic Diseases. SCPA202: Basic Pathology Genetic Diseases SCPA202: Basic Pathology Amornrat N. Jensen, Ph.D. Department of Pathobiology School of Science, Mahidol University amornrat.nar@mahidol.ac.th Genetic disease An illness caused by abnormalities

More information

Unifactorial or Single Gene Disorders. Hanan Hamamy Department of Genetic Medicine and Development Geneva University Hospital

Unifactorial or Single Gene Disorders. Hanan Hamamy Department of Genetic Medicine and Development Geneva University Hospital Unifactorial or Single Gene Disorders Hanan Hamamy Department of Genetic Medicine and Development Geneva University Hospital Training Course in Sexual and Reproductive Health Research Geneva 2011 Single

More information

Ch 7 Extending Mendelian Genetics

Ch 7 Extending Mendelian Genetics Ch 7 Extending Mendelian Genetics Studying Human Genetics A pedigree is a chart for tracing genes in a family. Used to determine the chances of offspring having a certain genetic disorder. Karyotype=picture

More information

PREIMPLANTATION GENETIC DIAGnosis

PREIMPLANTATION GENETIC DIAGnosis ORIGINAL CONTRIBUTION Preimplantation HLA Testing Yury Verlinsky, PhD Svetlana Rechitsky, PhD Tatyana Sharapova, MS Randy Morris, MD Mohammed Taranissi, MD Anver Kuliev, MD, PhD For editorial comment see

More information

Genetic Testing FOR DISEASES OF INCREASED FREQUENCY IN THE ASHKENAZI JEWISH POPULATION

Genetic Testing FOR DISEASES OF INCREASED FREQUENCY IN THE ASHKENAZI JEWISH POPULATION Carrier Screening and Diagnostic Testing for the Ashkenazi Jewish Population Genetic Testing FOR DISEASES OF INCREASED FREQUENCY IN THE ASHKENAZI JEWISH POPULATION Our Science. Your Care. An extensive

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY Policy Name: Policy Number: Approved By: CLINICAL MEDICAL POLICY Genetic Testing for Cystic Fibrosis MP-006-MD-DE Provider Notice Date: 11/1/2016 Original Effective Date: 12/1/2016 Annual Approval Date:

More information

Information for Recipient of Donor Oocytes

Information for Recipient of Donor Oocytes Introduction Thank you for expressing an interest as an oocyte recipient in our oocyte donation program at the Family Fertility Center. Our successful program was established since 1994 and is directed

More information

GENETIC SCREENING. Prof Dr Karen Sermon, MD, PhD LEARNING OBJECTIVES DISCLOSURE

GENETIC SCREENING. Prof Dr Karen Sermon, MD, PhD LEARNING OBJECTIVES DISCLOSURE GENETIC SCREENING Prof Dr Karen Sermon, MD, PhD LEARNING OBJECTIVES At the conclusion of this presentation, participants should be able to answer the following questions: What is (genetic) screening? Why

More information

Genetic screening. Martin Delatycki

Genetic screening. Martin Delatycki 7 Genetic screening Martin Delatycki Case study 1 Vanessa and John are planning a family. They see their general practitioner and ask whether they should have any tests prior to falling pregnant to maximise

More information

Lecture 17: Human Genetics. I. Types of Genetic Disorders. A. Single gene disorders

Lecture 17: Human Genetics. I. Types of Genetic Disorders. A. Single gene disorders Lecture 17: Human Genetics I. Types of Genetic Disorders A. Single gene disorders B. Multifactorial traits 1. Mutant alleles at several loci acting in concert C. Chromosomal abnormalities 1. Physical changes

More information

Basic Definitions. Dr. Mohammed Hussein Assi MBChB MSc DCH (UK) MRCPCH

Basic Definitions. Dr. Mohammed Hussein Assi MBChB MSc DCH (UK) MRCPCH Basic Definitions Chromosomes There are two types of chromosomes: autosomes (1-22) and sex chromosomes (X & Y). Humans are composed of two groups of cells: Gametes. Ova and sperm cells, which are haploid,

More information

Classifications of genetic disorders disorders

Classifications of genetic disorders disorders Classifications of genetic disorders Dr. Liqaa M. Sharifi Human diseases in general can roughly be classified in to: 1-Those that are genetically determined. 2-Those that are almost entirely environmentally

More information

Committee Paper SCAAC(05/09)01. ICSI guidance. Hannah Darby and Rachel Fowler

Committee Paper SCAAC(05/09)01. ICSI guidance. Hannah Darby and Rachel Fowler Committee Paper Committee: Scientific and Clinical Advances Advisory Committee Meeting Date: 12 May 2009 Agenda Item: 4 Paper Number: SCAAC(05/09)01 Paper Title: ICSI guidance Author: Hannah Darby and

More information

Understanding the Human Karyotype Colleen Jackson Cook, Ph.D.

Understanding the Human Karyotype Colleen Jackson Cook, Ph.D. Understanding the Human Karyotype Colleen Jackson Cook, Ph.D. SUPPLEMENTAL READING Nussbaum, RL, McInnes, RR, and Willard HF (2007) Thompson and Thompson Genetics in Medicine, 7th edition. Saunders: Philadelphia.

More information

Practical Preimplantation Genetic Diagnosis

Practical Preimplantation Genetic Diagnosis Practical Preimplantation Genetic Diagnosis Yury Verlinsky and Anver Kuliev Practical Preimplantation Genetic Diagnosis With 125 Figures Yury Verlinsky, PhD Anver Kuliev, MD, PhD Reproductive Genetics

More information

Genetic Disorders. and. blood vessels the and. How many genes are affected by this deletion? Turner s Syndrome- An incomplete or missing chromosome

Genetic Disorders. and. blood vessels the and. How many genes are affected by this deletion? Turner s Syndrome- An incomplete or missing chromosome Genetic Disorders A genetic disorder is an abnormality in the. They can range for a deletion of a gene to the deletion of an entire chromosome. List the types of genetic disorders. Williams Syndrome- A

More information

TEST INFORMATION Test: CarrierMap GEN (Genotyping) Panel: CarrierMap Expanded Diseases Tested: 311 Genes Tested: 299 Mutations Tested: 2647

TEST INFORMATION Test: CarrierMap GEN (Genotyping) Panel: CarrierMap Expanded Diseases Tested: 311 Genes Tested: 299 Mutations Tested: 2647 Ordering Practice Jane Smith John Smith Practice Code: 675 Miller MD 374 Broadway New York, NY 10000 Physician: Dr. Frank Miller Report Generated: 2016-02-03 DOB: 1973-02-19 Gender: Female Ethnicity: European

More information

INFERTILITY SERVICES

INFERTILITY SERVICES INFERTILITY SERVICES Protocol: OBG036 Effective Date: August 1, 2018 Table of Contents Page COMMERCIAL COVERAGE RATIONALE... 1 DEFINITIONS... 4 MEDICARE AND MEDICAID COVERAGE RATIONALE... 5 REFERENCES...

More information

GENETICS ROTATION OBJECTIVES MATERNAL-FETAL MEDICINE FELLOWSHIP

GENETICS ROTATION OBJECTIVES MATERNAL-FETAL MEDICINE FELLOWSHIP GENETICS ROTATION OBJECTIVES MATERNAL-FETAL MEDICINE FELLOWSHIP University of New Mexico 1. General Description: UNM MFM fellows rotate through genetics during their PGY5 and PGY7 years. The PGY5 fellow

More information

SNP array-based analyses of unbalanced embryos as a reference to distinguish between balanced translocation carrier and normal blastocysts

SNP array-based analyses of unbalanced embryos as a reference to distinguish between balanced translocation carrier and normal blastocysts J Assist Reprod Genet (2016) 33:1115 1119 DOI 10.1007/s10815-016-0734-0 TECHNOLOGICAL INNOVATIONS SNP array-based analyses of unbalanced embryos as a reference to distinguish between balanced translocation

More information

Gene Expression and Mutation

Gene Expression and Mutation Gene Expression and Mutation GENE EXPRESSION: There are hormonal and environmental factors that may cause the expression of some genetic information. Some examples are: 1. The two- colour pattern of some

More information

IVF AND PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) WHAT THE COMMUNITY PHYSICIAN NEEDS TO KNOW

IVF AND PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) WHAT THE COMMUNITY PHYSICIAN NEEDS TO KNOW IVF AND PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) WHAT THE COMMUNITY PHYSICIAN NEEDS TO KNOW Jon Havelock, MD, FRCSC, FACOG Co-Director - PCRM Disclosure No conflict of interest in relation

More information

PREIMPLANTATION GENETIC DIAGNOSIS

PREIMPLANTATION GENETIC DIAGNOSIS PREIMPLANTATION GENETIC DIAGNOSIS Peter Braude, Susan Pickering, Frances Flinter and Caroline Mackie Ogilvie Preimplantation genetic diagnosis (PGD) is an evolving technique that provides a practical alternative

More information

BIO113 Exam 2 Ch 4, 10, 13

BIO113 Exam 2 Ch 4, 10, 13 BIO113 Exam 2 Ch 4, 10, 13 See course outline for specific reading assignments Study notes and focus on terms and concepts The images in the textbook are useful CELLS (pg. 37) The basic unit of life living

More information

Fertility 101. About SCRC. A Primary Care Approach to Diagnosing and Treating Infertility. Definition of Infertility. Dr.

Fertility 101. About SCRC. A Primary Care Approach to Diagnosing and Treating Infertility. Definition of Infertility. Dr. Dr. Shahin Ghadir A Primary Care Approach to Diagnosing and Treating Infertility St. Charles Bend Grand Rounds November 30, 2018 I have no conflicts of interest to disclose. + About SCRC State-of-the-art

More information

This fact sheet describes the condition Fragile X and includes a discussion of the symptoms, causes and available testing.

This fact sheet describes the condition Fragile X and includes a discussion of the symptoms, causes and available testing. 11111 Fact Sheet 54 FRAGILE X SYNDROME This fact sheet describes the condition Fragile X and includes a discussion of the symptoms, causes and available testing. In summary Fragile X is a condition caused

More information

What is the relationship between genes and chromosomes? Is twinning genetic or can a person choose to have twins?

What is the relationship between genes and chromosomes? Is twinning genetic or can a person choose to have twins? WHAT WILL YOU KNOW? What is the relationship between genes and chromosomes? Is twinning genetic or can a person choose to have twins? How could a person have the gene for something that is never apparent?

More information

Carrier Screening for Genetic Diseases

Carrier Screening for Genetic Diseases Medical Policy Manual Genetic Testing, Policy No. 81 Carrier Screening for Genetic Diseases Next Review: September 2018 Last Review: December 2017 Effective: January 1, 2018 IMPORTANT REMINDER Medical

More information

PATIENT EDUCATION. Cystic Fibrosis Carrier Testing

PATIENT EDUCATION. Cystic Fibrosis Carrier Testing PATIENT EDUCATION Cystic Fibrosis Carrier Testing Introduction Cystic fibrosis carrier testing before or during pregnancy can help determine your risk of having a child with cystic fibrosis. This information

More information

Genetic Disorders. PART ONE: Detecting Genetic Disorders. Amniocentesis Chorionic villus sampling Karyotype Triple Screen Blood Test

Genetic Disorders. PART ONE: Detecting Genetic Disorders. Amniocentesis Chorionic villus sampling Karyotype Triple Screen Blood Test Genetic Disorders PART ONE: Detecting Genetic Disorders Amniocentesis Chorionic villus sampling Karyotype Triple Screen Blood Test Amniocentesis A technique for determining genetic abnormalities in a fetus

More information

CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi

CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi 2 CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE Dr. Bahar Naghavi Assistant professor of Basic Science Department, Shahid Beheshti University of Medical Sciences, Tehran,Iran 3 Introduction Over 4000

More information

Chapter 4 PEDIGREE ANALYSIS IN HUMAN GENETICS

Chapter 4 PEDIGREE ANALYSIS IN HUMAN GENETICS Chapter 4 PEDIGREE ANALYSIS IN HUMAN GENETICS Chapter Summary In order to study the transmission of human genetic traits to the next generation, a different method of operation had to be adopted. Instead

More information

Genetic counselling in PGD

Genetic counselling in PGD Genetic counselling in PGD Sérgio Castedo Serviço de Genética Faculdade de Medicina do Porto scastedo@netcabo.pt Disclosure of interests Sérgio Castedo is the CEO of GDPN, a private genetics diagnostic

More information

Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis

Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis Clinical Appropriateness Guidelines Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis EFFECTIVE OCTOBER 14, 2017 Appropriate.Safe.Affordable 2017 AIM Specialty Health 2068-1017

More information

Each person has a unique set of characteristics, such as eye colour, height and blood group.

Each person has a unique set of characteristics, such as eye colour, height and blood group. 1 of 51 2 of 51 What is inheritance? 3 of 51 Each person has a unique set of characteristics, such as eye colour, height and blood group. A person s characteristics are determined by a combination of the

More information

but it still needs a bit of work

but it still needs a bit of work but it still needs a bit of work jc@embryos.net Reprogenetics ART Institute of Washington Life Global Principle investigator of cytoplasmic transfer series (1996-2001) Is there an alternative to MRT? Lessons

More information

Related Policies None

Related Policies None Medical Policy MP 2.04.107 BCBSA Ref. Policy: 2.04.107 Last Review: 04/30/2018 Effective Date: 04/30/0218 Section: Medicine Related Policies None DISCLAIMER Our medical policies are designed for informational

More information

Preimplantation genetic diagnosis

Preimplantation genetic diagnosis Preimplantation genetic diagnosis Borut Peterlin Clinical institute of medical genetics, University Medical Centre Ljubljana Outline of the presentation Primary prevention of genetic diseases Motivation

More information

IVF Michigan, Rochester Hills, Michigan, and Reproductive Genetics Institute, Chicago, Illinois

IVF Michigan, Rochester Hills, Michigan, and Reproductive Genetics Institute, Chicago, Illinois FERTILITY AND STERILITY VOL. 80, NO. 4, OCTOBER 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. CASE REPORTS Preimplantation

More information

Increase your chance of IVF Success. PGT-A Preimplantation Genetic Testing for Aneuploidy (PGS 2.0)

Increase your chance of IVF Success. PGT-A Preimplantation Genetic Testing for Aneuploidy (PGS 2.0) Increase your chance of IVF Success PGT-A Preimplantation Genetic Testing for Aneuploidy (PGS 2.0) What is PGT-A? PGT-A, or Preimplantation Genetic Testing for Aneuploidy (PGS 2.0), is a type of genomic

More information

NOTES: : HUMAN HEREDITY

NOTES: : HUMAN HEREDITY NOTES: 14.1-14.2: HUMAN HEREDITY Human Genes: The human genome is the complete set of genetic information -it determines characteristics such as eye color and how proteins function within cells Recessive

More information

The preventative role of preimplantation genetic diagnosis?

The preventative role of preimplantation genetic diagnosis? The preventative role of preimplantation genetic diagnosis? Alison Lashwood Consultant Genetic Counsellor & Clinical Lead in PGD PGDGenetics@gstt.nhs.uk www.pgd.org.uk Where it all starts.. Kay & John

More information

Fragile X Syndrome and Infertility Case Example - Not One, but Three

Fragile X Syndrome and Infertility Case Example - Not One, but Three Vol. 008 Fragile X Syndrome and Infertility Fragile X Syndrome and Infertility Case Example - Not One, but Three Abstract A case review of a female patient who was treated for infertility of unknown reasons

More information

FAMILY PLANNING DOESN T HAVE TO BE ONE OF THEM

FAMILY PLANNING DOESN T HAVE TO BE ONE OF THEM THE ESSENTIAL PANEL There are many unknowns in life. FAMILY PLANNING DOESN T HAVE TO BE ONE OF THEM PLANNING FOR A FAMILY IS A BIG DECISION TAKE STEPS TOWARD A HEALTHY FUTURE WITH NXGEN GENETIC CARRIER

More information

CELLS. Some human cells

CELLS. Some human cells CELLS the basic unit of life living things are composed of at least one cell cells metabolize (obtain energy, use energy, make waste) cells can reproduce cells sense and respond to the environment red

More information

LIST OF INVESTIGATIONS

LIST OF INVESTIGATIONS Karyotyping: K001 K002 LIST OF INVESTIGATIONS SAMPLE CONTAINER TYPE cells For Karyotyping [Single] cells For Karyotyping [Couple] Vacutainer Vacutainer 7-8 7-8 K003 Fetal Blood Sample For Karyotyping Vacutainer

More information

Preimplantation Genetic Diagnosis (PGD) single gene disorders. A patient guide

Preimplantation Genetic Diagnosis (PGD) single gene disorders. A patient guide Preimplantation Genetic Diagnosis (PGD) single gene disorders A patient guide Reproductive Genetic Innovations, LLC 2910 MacArthur Boulevard Northbrook, Illinois 60062 Phone: (847) 400-1515 Fax: (847)

More information

Lab Activity Report: Mendelian Genetics - Genetic Disorders

Lab Activity Report: Mendelian Genetics - Genetic Disorders Name Date Period Lab Activity Report: Mendelian Genetics - Genetic Disorders Background: Sometimes genetic disorders are caused by mutations to normal genes. When the mutation has been in the population

More information

B1 Revision You and Your Genes. You and Your Genes (B1) Revision for Exam

B1 Revision You and Your Genes. You and Your Genes (B1) Revision for Exam B1 Revision You and Your Genes You and Your Genes (B1) Revision for Exam What makes us all different? Organisms inherit information from their parents. This controls how they develop, so children look

More information

Genetics and Reproductive Options for SMA Families Annual SMA Conference Dallas, Texas Friday, June 15, 2017

Genetics and Reproductive Options for SMA Families Annual SMA Conference Dallas, Texas Friday, June 15, 2017 Genetics and Reproductive Options for SMA Families 2018 Annual SMA Conference Dallas, Texas Friday, June 15, 2017 Part 1: SMA and Genetics Louise R Simard, PhD Part 2: SMA Carrier Screening Melissa Gibbons,

More information

STEM CELL RESEARCH: MEDICAL PROGRESS WITH RESPONSIBILITY

STEM CELL RESEARCH: MEDICAL PROGRESS WITH RESPONSIBILITY STEM CELL RESEARCH: MEDICAL PROGRESS WITH RESPONSIBILITY A REPORT FROM THE CHIEF MEDICAL OFFICER S EXPERT GROUP REVIEWING THE POTENTIAL OF DEVELOPMENTS IN STEM CELL RESEARCH AND CELL NUCLEAR REPLACEMENT

More information

Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis

Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis Medical Coverage Policy Effective Date... 1/15/2018 Next Review Date... 8/15/2018 Coverage Policy Number... 0514 Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis Table of Contents

More information

Lesson Overview. Human Chromosomes. Lesson Overview. Human Chromosomes

Lesson Overview. Human Chromosomes. Lesson Overview. Human Chromosomes Lesson Overview Karyotypes A genome is the full set of genetic information that an organism carries in its DNA. A study of any genome starts with chromosomes, the bundles of DNA and protein found in the

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY CLINICAL MEDICAL POLICY Policy Name: Genetic Testing for Cystic Fibrosis Policy Number: MP-006-MD-DE Approved By: Medical Management Provider Notice Date: 04/15/2018; 11/01/2016 Issue Date: 05/15/2018

More information

Genetic Assessment and Counseling

Genetic Assessment and Counseling Genetic Assessment and Counseling Genetic counseling is the communication of information and advice about inherited conditions and a person seeking such advice is called a consultand. This process includes

More information

THE CHROMOSOMAL BASIS OF INHERITANCE CHAPTER 15

THE CHROMOSOMAL BASIS OF INHERITANCE CHAPTER 15 THE CHROMOSOMAL BASIS OF INHERITANCE CHAPTER 15 What you must know: Inheritance in sex-linked genes. Inheritance of linked genes and chromosomal mapping. How alteration of chromosome number or structurally

More information

The Six Ws of DNA testing A scenario-based activity introducing medical applications of DNA testing

The Six Ws of DNA testing A scenario-based activity introducing medical applications of DNA testing The Six Ws of DNA testing A scenario-based activity introducing medical applications of DNA testing Overview This activity introduces a number of different ways that genetic tests can be used in medicine.

More information